JP2010514779A - 逆配列hiv−tatポリペプチドを用いる輸送分子 - Google Patents
逆配列hiv−tatポリペプチドを用いる輸送分子 Download PDFInfo
- Publication number
- JP2010514779A JP2010514779A JP2009544158A JP2009544158A JP2010514779A JP 2010514779 A JP2010514779 A JP 2010514779A JP 2009544158 A JP2009544158 A JP 2009544158A JP 2009544158 A JP2009544158 A JP 2009544158A JP 2010514779 A JP2010514779 A JP 2010514779A
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- cargo
- transport
- cargo molecule
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
本出願は、2006年12月29日に出願された米国仮出願第60/882,639号の優先権を主張し、その米国仮出願の内容は、全体として参照により本明細書に組み入れられている。
本発明の好ましい輸送分子は、HIV−TAT塩基性領域アミノ酸配列(天然のHIV−TATタンパク質のアミノ酸49〜57位)の逆配列に対応する配列を有するポリペプチドの存在によって特徴づけられる。このHIV−TAT塩基性領域の逆配列RRRQRRKKR(配列番号1)を、以下、「逆配列ポリペプチド」と呼ぶものとし、コンジュゲートを形成するのに所望のカーゴ分子に共有結合により付着(attach)しても、非共有結合により付着してもよい。特定の実施形態において、直接か又はペプチド若しくは重合体リンカーを介してかのいずれかで、1又は複数の逆配列ポリペプチドを所望のカーゴ分子に共有結合により付着することが有利である。例えば、逆配列ポリペプチドは、本明細書に記載されているように、化学架橋又は遺伝子融合によってカーゴ分子に有利に付着することができる。
本発明は、一般的に、有用な率で標的細胞に入る又は生体膜を透過することが本質的にできない、小分子、並びにタンパク質、核酸、及び多糖などの高分子の治療的、予防的、又は診断的な細胞内送達又は膜貫通送達に適用できる。本発明の方法及び組成物は、ヒトを含む任意の生物体に適用してもよい。本発明の方法及び組成物はまた、子宮内で動物及びヒトに適用してもよい。本発明の一つの好ましい実施形態によれば、輸送分子−カーゴコンジュゲートの生きたヒト又は動物の体内又は表面への導入後、カーゴ分子は、様々な器官及び組織の細胞へ送達される。例えば、カーゴ分子/輸送分子コンジュゲートを、カーゴ分子の導入が望まれる細胞と接触させてもよい。結果として、コンジュゲートは細胞に入り、核の中へ移行する。別の実施形態において、カーゴ分子/輸送分子コンジュゲートを、膜の表面に投与し、カーゴ分子/輸送分子コンジュゲートの膜貫通透過を引き起こす。例えば、カーゴ分子の治療作用が有効であろう領域にカーゴ分子/輸送分子コンジュゲートを局所投与してもよい。特に好ましい実施形態において、カーゴ分子はある血清型のボツリヌス毒素であり、深いしわ(furrow)又はしわ(wrinkle)の出現を減少させるために深いしわ又はしわがある皮膚の領域にカーゴ分子/輸送分子コンジュゲートを局所投与する。
皮膚膜の調製:ヒト皮膚膜を凍結した皮膚試料(腹部手術後すぐの単一のドナー)から調製した。解凍後、皮膚を、皮膚採取器(Dermatome 25 mm)(Nouvag GmbH, Germany)を用いて約400μmの記録された厚さで採取した。
試験物質の125I標識:Neuronox製品を含む1つのバイアルの内容物を、100μL 50mM KH2PO4緩衝液、pH7.2中に再構成した。ヨウ素化の間、37MBq Na125I(10μl)、20μlの約100,000倍希釈した過酸化水素水溶液(30%(v/v)ペリヒドロール)、及び20μlラクトペルオキシダーゼ(4μg/10μL水)を、Neuronox(登録商標)製品を含むバイアルに加えた。約60秒後、利用可能なタンパク質(毒素、アルブミンなど)とまだ反応していない過剰125Iを除去するためにリン酸緩衝液中50μLチロシン溶液(1mg/mL)の添加によってヨウ素化を停止した。1分後、125I(L−チロシンと結合した)を、0.5%(w/v)BSA含有アッセイ緩衝液と平衡に達した約10mL容量のSephadex G25微細カラムを用いることによって放射標識タンパク質から分離した。約250μLの画分を収集した。細画分を放射活性測定のために採取した。画分をさらに使用するまで、2〜10℃で保存した。
放射活性の測定:完全性試験の試料における放射活性を、Wallac Pharmacia モデルS1414シンチレーションカウンターにおけるクエンチ補正についてDOT−DPMTM(スペクトルライブラリー及び外部標準スペクトルを用いるデジタルオーバーレイ技術)を用いる液体シンチレーションカウンティング(LSC,liquid scintillation counting)によって測定した。装置についての較正手順は試験施設で確立されている。
全吸収は、レセプター液、レセプターコンパートメント洗浄液、及び皮膚(テープ条片を除く)に存在する化合物関連放射活性の量として定義される。
試験品目の経皮吸収
[125I]Neuronox(登録商標)の経皮吸収をヒト皮膚膜上で評価した。暴露時間は24時間であった。(組織)分布は表1に示されている。
Claims (15)
- 配列番号1によるアミノ酸配列を有する逆配列ポリペプチドを含む、カーゴ分子の送達のための輸送分子。
- 逆配列ポリペプチドがカーゴ分子に共有結合により付着している、請求項1に記載の輸送分子。
- 逆配列ポリペプチドが、カーゴ分子に非共有結合により付着した正電荷をもつ骨格に共有結合している、請求項1に記載の輸送分子。
- 逆配列ポリペプチドが、カーゴ分子に非共有結合した正電荷をもつ骨格に共有結合している、請求項3に記載の輸送分子。
- カーゴ分子の生体膜を通した透過を増強する、請求項1に記載の輸送分子。
- 生体膜が皮膚に存在する、請求項5に記載の輸送分子。
- カーゴ分子の細胞内透過を増強する、請求項1に記載の輸送分子。
- 配列番号1に示すアミノ酸配列を有する逆配列ポリペプチドを含む輸送分子;及び
カーゴ分子
を含む、カーゴ分子の送達のためのコンジュゲート。 - 輸送分子がカーゴ分子に共有結合により付着している、請求項8に記載のコンジュゲート。
- 輸送分子がカーゴ分子に非共有結合により付着している、請求項8に記載のコンジュゲート。
- カーゴ分子が治療薬である、請求項8に記載のコンジュゲート。
- 治療薬が、ペプチド、タンパク質、オリゴヌクレオチド、酵素、及び抗原からなる群から選択される、請求項11に記載のコンジュゲート。
- 治療薬がある血清型のボツリヌス毒素又はその断片に由来する、請求項11記載のコンジュゲート。
- 診断薬が、放射線不透過性造影剤、常磁性造影剤、超常磁性造影剤、及びCT造影剤からなる群から選択される、請求項13に記載のコンジュゲート。
- カーゴ分子を選択するステップ;
輸送分子を選択するステップ;
前記カーゴ分子を前記輸送分子に共有結合又は非共有結合のいずれかにより結合して、カーゴ分子/輸送分子コンジュゲートを形成するステップ;及び
カーゴ分子の細胞内送達又は膜貫通送達を引き起こすために前記コンジュゲートを標的細胞又は膜に投与するステップ
を含む、疾患の治療方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88263906P | 2006-12-29 | 2006-12-29 | |
PCT/US2007/087241 WO2008082885A2 (en) | 2006-12-29 | 2007-12-12 | Transport molecules using reverse sequence hiv-tat polypeptides |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013163127A Division JP2014012680A (ja) | 2006-12-29 | 2013-08-06 | 逆配列hiv−tatポリペプチドを用いる輸送分子 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010514779A true JP2010514779A (ja) | 2010-05-06 |
JP2010514779A5 JP2010514779A5 (ja) | 2011-02-03 |
Family
ID=39589169
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009544158A Ceased JP2010514779A (ja) | 2006-12-29 | 2007-12-12 | 逆配列hiv−tatポリペプチドを用いる輸送分子 |
JP2013163127A Pending JP2014012680A (ja) | 2006-12-29 | 2013-08-06 | 逆配列hiv−tatポリペプチドを用いる輸送分子 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013163127A Pending JP2014012680A (ja) | 2006-12-29 | 2013-08-06 | 逆配列hiv−tatポリペプチドを用いる輸送分子 |
Country Status (16)
Country | Link |
---|---|
US (2) | US20080226551A1 (ja) |
EP (1) | EP2109363A4 (ja) |
JP (2) | JP2010514779A (ja) |
KR (1) | KR20090102833A (ja) |
CN (1) | CN101583274A (ja) |
AR (1) | AR064707A1 (ja) |
AU (1) | AU2007340158A1 (ja) |
BR (1) | BRPI0720729A2 (ja) |
CA (1) | CA2672886C (ja) |
CO (1) | CO6220837A2 (ja) |
CR (1) | CR10921A (ja) |
MX (1) | MX2009007070A (ja) |
NO (1) | NO20092697L (ja) |
NZ (1) | NZ598159A (ja) |
TW (1) | TW200848080A (ja) |
WO (1) | WO2008082885A2 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
KR101284710B1 (ko) | 2004-03-03 | 2013-07-23 | 레반스 테라퓨틱스, 아이엔씨. | 국소 진단제 및 치료제의 수송을 위한 조성물 및 방법 |
BRPI0608249A2 (pt) * | 2005-03-03 | 2009-12-08 | Revance Therapeutics Inc | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica |
CN101842107B (zh) | 2007-07-26 | 2014-04-23 | 雷文斯治疗公司 | 抗微生物肽,组合物和使用方法 |
PL2271670T3 (pl) | 2008-03-14 | 2015-05-29 | Allergan Inc | Testy aktywności serotypu A toksyny botulinowej oparte na immunologii |
WO2010047216A1 (ja) | 2008-10-23 | 2010-04-29 | 国立大学法人 東京大学 | microRNAの機能阻害法 |
PT2413947T (pt) | 2009-04-01 | 2020-05-28 | Revance Therapeutics Inc | Métodos e composições para tratar condições de pele associadas à hiper-reatividade vascular |
US9623117B2 (en) * | 2011-04-04 | 2017-04-18 | Wisconsin Alumni Research Foundation | Method for selective targeting and entry of bacterial toxins to cells |
WO2014066916A2 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
BR112023012422A2 (pt) | 2021-01-24 | 2023-12-12 | Michael David Forrest | Inibidores da atp sintase - usos cosmético e terapêutico |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006511448A (ja) * | 2002-06-14 | 2006-04-06 | メディミューン,インコーポレイテッド | 安定化された抗呼吸器合胞体ウイルス(rsv)抗体製剤 |
JP2006514537A (ja) * | 2002-07-15 | 2006-05-11 | ノバルティス アクチエンゲゼルシャフト | アルスロバクター由来のHsp70 |
WO2006050930A2 (en) * | 2004-11-12 | 2006-05-18 | Xigen S.A. | Conjugates with enhanced cell uptake activity |
JP2006515742A (ja) * | 2002-08-27 | 2006-06-08 | ブリストル−マイヤーズ スクイブ カンパニー | 乳癌細胞でのプロテインチロシンキナーゼおよび/またはプロテインチロシンキナーゼ経路と相互作用および/またはモデュレートする化合物の活性を予測するためのポリヌクレオチドの同定 |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4078060A (en) * | 1976-05-10 | 1978-03-07 | Richardson-Merrell Inc. | Method of inducing an estrogenic response |
US4434228A (en) * | 1982-04-20 | 1984-02-28 | Genex Corporation | Immobilization of biological materials in condensed polyalkyleneimine polymers |
US4816568A (en) * | 1986-05-16 | 1989-03-28 | International Minerals & Chemical Corp. | Stabilization of growth hormones |
US5420105A (en) * | 1988-09-23 | 1995-05-30 | Gustavson; Linda M. | Polymeric carriers for non-covalent drug conjugation |
US5252713A (en) * | 1988-09-23 | 1993-10-12 | Neorx Corporation | Polymeric carriers for non-covalent drug conjugation |
US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5652122A (en) * | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
US6316003B1 (en) * | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
US5629020A (en) * | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
US5709861A (en) * | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
US6986893B2 (en) * | 1993-12-28 | 2006-01-17 | Allergan, Inc. | Method for treating a mucus secretion |
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
NO180167C (no) * | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
GB9600272D0 (en) * | 1996-01-06 | 1996-03-06 | Univ Nottingham | Polymers |
EP0975370B9 (en) * | 1997-05-21 | 2004-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
EP1044280A1 (en) * | 1997-12-12 | 2000-10-18 | Onyx Pharmaceuticals, Inc. | SELECTIVE KILLING AND DIAGNOSIS OF p53?+ NEOPLASTIC CELLS |
WO1999042091A2 (en) * | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
US6261679B1 (en) * | 1998-05-22 | 2001-07-17 | Kimberly-Clark Worldwide, Inc. | Fibrous absorbent material and methods of making the same |
MXPA01000271A (es) * | 1998-07-13 | 2002-10-17 | Expression Genetics Inc | Analogo de poliester de poli-lisina como un portador para el suministro de genes, soluble, biodegradable. |
US6280937B1 (en) * | 1998-08-14 | 2001-08-28 | Rigel Pharmaceuticals, Inc. | Shuttle vectors |
US6958147B1 (en) * | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
MXPA01004254A (es) * | 1998-10-27 | 2002-04-24 | Mayo Foundation | Metodos para intensificar la curacion de heridas. |
US6627632B2 (en) * | 1998-12-14 | 2003-09-30 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
US7056656B1 (en) * | 1999-01-25 | 2006-06-06 | University Of Medicine And Dentistry Of New Jersey | Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA |
US7008924B1 (en) * | 1999-07-21 | 2006-03-07 | Amgen, Inc. | VGF fusion polypeptides |
US6669951B2 (en) * | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US7229961B2 (en) * | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
US6730293B1 (en) * | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
EP1210121A2 (en) * | 1999-08-24 | 2002-06-05 | Cellgate Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
US20030104622A1 (en) * | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
US6544548B1 (en) * | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
US6458763B1 (en) * | 1999-09-17 | 2002-10-01 | Depuy Orthopeadics | Bone sialoprotein-based compositions for enhancing connective tissue repair |
US6610820B1 (en) * | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US6844324B1 (en) * | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
US7070807B2 (en) * | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
US20040109871A1 (en) * | 2000-01-06 | 2004-06-10 | Pascual David W. | M cell directed vaccines |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US20020009491A1 (en) * | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
JP3498041B2 (ja) * | 2000-05-29 | 2004-02-16 | 科研製薬株式会社 | プラルモレリン含有点鼻用製剤 |
US6670322B2 (en) * | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US20040033241A1 (en) * | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US20030215412A1 (en) * | 2000-07-21 | 2003-11-20 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US6696038B1 (en) * | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
US20020127247A1 (en) * | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
US20020086036A1 (en) * | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
US7255865B2 (en) * | 2000-12-05 | 2007-08-14 | Allergan, Inc. | Methods of administering botulinum toxin |
DE60233137D1 (de) * | 2001-02-16 | 2009-09-10 | Univ R | Transporter mit beabstandeten arginin-teilchen |
CA2367636C (en) * | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
AUPR621501A0 (en) * | 2001-07-06 | 2001-08-02 | Commonwealth Scientific And Industrial Research Organisation | Delivery of ds rna |
AU2002355730B2 (en) * | 2001-07-27 | 2007-09-13 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Botulinum toxin in the treatment or prevention of acne |
US20030109448A1 (en) * | 2001-11-07 | 2003-06-12 | Crowley Kathleen S. | Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells |
US7060498B1 (en) * | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
EP1461084A2 (en) * | 2001-12-11 | 2004-09-29 | The Board Of Trustees Of The Leland Stanford Junior University | Guanidinium transport reagents and conjugates |
US20030113349A1 (en) * | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
WO2003066859A2 (en) * | 2002-02-07 | 2003-08-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Amino acid sequences capable of facilitating penetration across a biological barrier |
CA2481479C (en) * | 2002-02-26 | 2012-12-11 | Maxygen, Inc. | Novel flavivirus antigens |
US6688311B2 (en) * | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
US20030215395A1 (en) * | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
US7459164B2 (en) * | 2002-05-28 | 2008-12-02 | Botulinum Toxin Research Associates, Inc. | Composition for therapeutic and cosmetic botulinum toxin |
JP2005538954A (ja) * | 2002-05-31 | 2005-12-22 | トーマス・ジェファーソン・ユニバーシティ | 分子の経上皮輸送用組成物及び方法 |
US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
US7071167B2 (en) * | 2002-11-13 | 2006-07-04 | L'oreal | Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines |
US6866856B2 (en) * | 2002-12-31 | 2005-03-15 | Avon Products, Inc. | Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis |
US20040192754A1 (en) * | 2003-03-24 | 2004-09-30 | Shapira Nathan Andrew | Methods for treating idiopathic hyperhidrosis and associated conditions |
DK2351844T3 (da) * | 2003-04-29 | 2014-09-22 | Sarepta Therapeutics Inc | Præparater til forøgelse af transport- og antisense-effektivitet af nukleinsyreanalog i celler |
US8871224B2 (en) * | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
CN1946431B (zh) * | 2004-03-03 | 2011-12-07 | 雷文斯治疗公司 | 用于肉毒毒素的局部施用和透皮递送的组合物和方法 |
KR101284710B1 (ko) * | 2004-03-03 | 2013-07-23 | 레반스 테라퓨틱스, 아이엔씨. | 국소 진단제 및 치료제의 수송을 위한 조성물 및 방법 |
US7691381B2 (en) * | 2004-04-15 | 2010-04-06 | Allergan, Inc. | Stabilized biodegradable neurotoxin implants |
US20060040882A1 (en) * | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
CA2799413A1 (en) * | 2004-07-26 | 2006-02-23 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition with a botulinum neurotoxin |
US20060024331A1 (en) * | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
EP1661912A1 (en) * | 2004-11-29 | 2006-05-31 | Xigen S.A. | Fusion protein comprising a BH3-domain of a BH3-only protein |
BRPI0608249A2 (pt) * | 2005-03-03 | 2009-12-08 | Revance Therapeutics Inc | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica |
US8114581B2 (en) * | 2005-09-15 | 2012-02-14 | The Regents Of The University Of California | Methods and compositions for detecting neoplastic cells |
WO2007071448A2 (en) * | 2005-12-23 | 2007-06-28 | Partnership & Corp. Technology Transfer | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation |
CN101842107B (zh) * | 2007-07-26 | 2014-04-23 | 雷文斯治疗公司 | 抗微生物肽,组合物和使用方法 |
SG172812A1 (en) * | 2008-12-31 | 2011-08-29 | Revance Therapeutics Inc | Injectable botulinum toxin formulations |
-
2007
- 2007-12-12 JP JP2009544158A patent/JP2010514779A/ja not_active Ceased
- 2007-12-12 EP EP07869157.3A patent/EP2109363A4/en not_active Withdrawn
- 2007-12-12 CA CA2672886A patent/CA2672886C/en not_active Expired - Fee Related
- 2007-12-12 AU AU2007340158A patent/AU2007340158A1/en not_active Abandoned
- 2007-12-12 CN CNA2007800483630A patent/CN101583274A/zh active Pending
- 2007-12-12 BR BRPI0720729-8A patent/BRPI0720729A2/pt not_active IP Right Cessation
- 2007-12-12 MX MX2009007070A patent/MX2009007070A/es not_active Application Discontinuation
- 2007-12-12 WO PCT/US2007/087241 patent/WO2008082885A2/en active Application Filing
- 2007-12-12 NZ NZ598159A patent/NZ598159A/xx not_active IP Right Cessation
- 2007-12-12 US US11/954,885 patent/US20080226551A1/en not_active Abandoned
- 2007-12-12 US US12/520,964 patent/US20100093639A1/en not_active Abandoned
- 2007-12-12 KR KR1020097015649A patent/KR20090102833A/ko not_active Application Discontinuation
- 2007-12-21 TW TW096149556A patent/TW200848080A/zh unknown
- 2007-12-28 AR ARP070105982A patent/AR064707A1/es unknown
-
2009
- 2009-07-13 CR CR10921A patent/CR10921A/es unknown
- 2009-07-17 NO NO20092697A patent/NO20092697L/no not_active Application Discontinuation
- 2009-07-29 CO CO09079071A patent/CO6220837A2/es not_active Application Discontinuation
-
2013
- 2013-08-06 JP JP2013163127A patent/JP2014012680A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006511448A (ja) * | 2002-06-14 | 2006-04-06 | メディミューン,インコーポレイテッド | 安定化された抗呼吸器合胞体ウイルス(rsv)抗体製剤 |
JP2006514537A (ja) * | 2002-07-15 | 2006-05-11 | ノバルティス アクチエンゲゼルシャフト | アルスロバクター由来のHsp70 |
JP2006515742A (ja) * | 2002-08-27 | 2006-06-08 | ブリストル−マイヤーズ スクイブ カンパニー | 乳癌細胞でのプロテインチロシンキナーゼおよび/またはプロテインチロシンキナーゼ経路と相互作用および/またはモデュレートする化合物の活性を予測するためのポリヌクレオチドの同定 |
WO2006050930A2 (en) * | 2004-11-12 | 2006-05-18 | Xigen S.A. | Conjugates with enhanced cell uptake activity |
Non-Patent Citations (1)
Title |
---|
JPN6012060910; Journal of controlled release. 2001, Vol.77, No.3, p.199-212 * |
Also Published As
Publication number | Publication date |
---|---|
MX2009007070A (es) | 2009-07-10 |
CO6220837A2 (es) | 2010-11-19 |
US20080226551A1 (en) | 2008-09-18 |
NZ598159A (en) | 2013-08-30 |
NO20092697L (no) | 2009-09-28 |
KR20090102833A (ko) | 2009-09-30 |
AR064707A1 (es) | 2009-04-22 |
WO2008082885A3 (en) | 2008-11-20 |
EP2109363A4 (en) | 2014-07-09 |
WO2008082885A2 (en) | 2008-07-10 |
US20100093639A1 (en) | 2010-04-15 |
CA2672886A1 (en) | 2008-07-10 |
AU2007340158A1 (en) | 2008-07-10 |
BRPI0720729A2 (pt) | 2014-04-08 |
CA2672886C (en) | 2015-02-10 |
CR10921A (es) | 2009-09-14 |
TW200848080A (en) | 2008-12-16 |
JP2014012680A (ja) | 2014-01-23 |
EP2109363A2 (en) | 2009-10-21 |
CN101583274A (zh) | 2009-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2672886C (en) | Transport molecules using reverse sequence hiv-tat polypeptides | |
US20210069224A1 (en) | Compositions and Methods for Topical and Diagnostic and Therapeutic Transport | |
US6730293B1 (en) | Compositions and methods for treating inflammatory diseases of the skin | |
US6759387B2 (en) | Compositions and methods for enhancing drug delivery across and into epithelial tissues | |
EP2928502B1 (en) | Conjugates of proteins and multivalent cell-penetrating peptides and their uses | |
Liang et al. | Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency | |
CA2438326A1 (en) | Compositions and methods for enhancing drug delivery across and into epithelial tissues | |
JP2007526330A (ja) | 多成分系生物学的輸送系 | |
Ichimizu et al. | Design and tuning of a cell-penetrating albumin derivative as a versatile nanovehicle for intracellular drug delivery | |
Clemons et al. | Examining efficacy of “tat-less” delivery of a peptide against the L-type calcium channel in cardiac ischemia–reperfusion injury | |
Bullok et al. | Permeation peptide conjugates for in vivo molecular imaging applications | |
CN109922817A (zh) | 用于诊断和治疗与细胞外基质周转相关的疾病的剂和方法 | |
Kameyama et al. | Distribution of immunoglobulin Fab fragment conjugated with HIV-1 REV peptide following intravenous administration in rats | |
EP3741854A1 (en) | Metal-binding peptide and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090619 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101207 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130218 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130225 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130319 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130411 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130806 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130918 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131111 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20140320 |